Neuroscience
A recent study, published in Science Translational Medicine, suggests hope for glioblastoma patients.
The approach, which included members from the Perelman School of Medicine at the University of Pennsylvania and the Novartis Institutes for BioMedical Research, involved engineering immune cells to seek out and attack a type of deadly brain cancer, beginning with its impact in mice. While it's still to early to indicate the potential effect and long-term benefits for people with gliobastoma, the results were found to be safe and effective at controlling tumor growth in mice with these modified cells. These results have paved the way for a newly opened clinical trial being conducted at Penn Medicine.
"Patients with this type of brain cancer have a very poor prognosis. Many survive less than 18 months following their diagnosis," said M. Sean Grady, MD, chair of the department of Neurosurgery. "We've brought together experts in an array of fields to develop an innovative personalized immunotherapy for certain brain cancers."
The new trial is led by Donald M. O'Rourke, MD, associate professor of Neurosurgery, who oversees an interdisciplinary collaboration of neurosurgeons, neuro-oncologists, neuropathologists, immunologists, and transfusion medicine experts.
Learn more about how the preclinical study results have paved the way for this newly opened clinical trial.
Interested in learning more about current neurosurgery clinical trials?
- Brain Tumor Symposium: Bridging Precision Science And Personalized Medicine
Penn Medicine’s Abramson Cancer Center and Brain Tumor Center are pleased to host the Penn Oncology Neurosurgery Symposium. Full program overviewWhen:Friday, June 6, 2014 Where:Smilow Center for Translational Research Perelman School of Medicine at...
- Focus On Brain Cancer: Discovery To Recovery
The Focus On Brain Cancer: Discovery to Recovery conference is sponsored by the Abramson Cancer Center. The Focus On Brain Cancer conference is for adults who are newly diagnosed, in treatment of survivors of brain cancer. At this conference, adults with...
- Antiviral May Boost Survival In Brain Cancer
Donald M. O'Rourke, MDAntiviral therapy against cytomegalovirus (CMV) -- typically only thought of as a threat in immunosuppressed patients -- was linked to dramatically improved survival in patients with glioblastoma, based on one center's experience....
- Improving Treatment For Brain Cancer Patients
Steven Brem, MDThe American Society of Clinical Oncology (ASCO) features an interview with Steven Brem, MD in its June issue of The ASCO POST. Dr. Brem, Co-Director of the Penn Brain Tumor Center and Professor of Neurosurgery, talks about the current...
- Steven Brem, Md Receives American Brain Tumor Association Award
Steven Brem, MD, Professor of Neurosurgery, Chief of the Division of Neurosurgical Oncology and Co-Director of the Penn Brain Tumor Center, has received the first Joel A. Gingras, Jr. award given by the American Brain Tumor Association (ABTA). Dr. Brem...
Neuroscience
Personalized T Cell Therapy Shows Promise in Stopping Brain Tumor Growth
A recent study, published in Science Translational Medicine, suggests hope for glioblastoma patients.
The approach, which included members from the Perelman School of Medicine at the University of Pennsylvania and the Novartis Institutes for BioMedical Research, involved engineering immune cells to seek out and attack a type of deadly brain cancer, beginning with its impact in mice. While it's still to early to indicate the potential effect and long-term benefits for people with gliobastoma, the results were found to be safe and effective at controlling tumor growth in mice with these modified cells. These results have paved the way for a newly opened clinical trial being conducted at Penn Medicine.
 |
| Donald M. O'Rourke, MD |
The new trial is led by Donald M. O'Rourke, MD, associate professor of Neurosurgery, who oversees an interdisciplinary collaboration of neurosurgeons, neuro-oncologists, neuropathologists, immunologists, and transfusion medicine experts.
Learn more about how the preclinical study results have paved the way for this newly opened clinical trial.
Interested in learning more about current neurosurgery clinical trials?
- Brain Tumor Symposium: Bridging Precision Science And Personalized Medicine
Penn Medicine’s Abramson Cancer Center and Brain Tumor Center are pleased to host the Penn Oncology Neurosurgery Symposium. Full program overviewWhen:Friday, June 6, 2014 Where:Smilow Center for Translational Research Perelman School of Medicine at...
- Focus On Brain Cancer: Discovery To Recovery
The Focus On Brain Cancer: Discovery to Recovery conference is sponsored by the Abramson Cancer Center. The Focus On Brain Cancer conference is for adults who are newly diagnosed, in treatment of survivors of brain cancer. At this conference, adults with...
- Antiviral May Boost Survival In Brain Cancer
Donald M. O'Rourke, MDAntiviral therapy against cytomegalovirus (CMV) -- typically only thought of as a threat in immunosuppressed patients -- was linked to dramatically improved survival in patients with glioblastoma, based on one center's experience....
- Improving Treatment For Brain Cancer Patients
Steven Brem, MDThe American Society of Clinical Oncology (ASCO) features an interview with Steven Brem, MD in its June issue of The ASCO POST. Dr. Brem, Co-Director of the Penn Brain Tumor Center and Professor of Neurosurgery, talks about the current...
- Steven Brem, Md Receives American Brain Tumor Association Award
Steven Brem, MD, Professor of Neurosurgery, Chief of the Division of Neurosurgical Oncology and Co-Director of the Penn Brain Tumor Center, has received the first Joel A. Gingras, Jr. award given by the American Brain Tumor Association (ABTA). Dr. Brem...